Financials Predictive Oncology Inc.

Equities

POAI

US74039M3097

Medical Equipment, Supplies & Distribution

Market Closed - Nasdaq 04:30:00 2024-04-26 pm EDT 5-day change 1st Jan Change
1.51 USD -9.04% Intraday chart for Predictive Oncology Inc. +29.06% -54.10%

Valuation

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Capitalization 1 8.724 10.24 12.95 62.42 24.15 13.37
Enterprise Value (EV) 1 10.2 15.62 18.14 35.1 2.255 7.496
P/E ratio -0.78 x -0.38 x -0.33 x -2.64 x -0.87 x -0.94 x
Yield - - - - - -
Capitalization / Revenue 6.18 x 7.26 x 10.3 x 43.9 x 16 x 7.51 x
EV / Revenue 7.22 x 11.1 x 14.5 x 24.7 x 1.5 x 4.21 x
EV / EBITDA -1.32 x -1.36 x -1.58 x -2.89 x -0.16 x -0.57 x
EV / FCF -5.12 x 7.34 x -2.92 x -3.9 x -0.32 x -0.88 x
FCF Yield -19.5% 13.6% -34.3% -25.6% -312% -114%
Price to Book 166 x 0.95 x 5.49 x 1.55 x 1.11 x 1.62 x
Nbr of stocks (in thousands) 70.5 196 884 3,279 3,938 4,063
Reference price 2 123.8 52.20 14.65 19.04 6.132 3.290
Announcement Date 4/1/19 4/1/20 3/15/21 3/31/22 3/21/23 3/28/24
1USD in Million2USD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Net sales 1 1.412 1.412 1.252 1.421 1.505 1.78
EBITDA 1 -7.714 -11.48 -11.46 -12.13 -13.95 -13.18
EBIT 1 -7.861 -12.08 -12.48 -13.47 -15.27 -13.92
Operating Margin -556.89% -855.81% -996.87% -948.25% -1,014.16% -782.06%
Earnings before Tax (EBT) 1 -10.09 -19.39 -25.88 -20.32 -25.74 -13.98
Net income 1 -10.09 -19.39 -25.88 -19.66 -25.74 -13.98
Net margin -714.51% -1,373.71% -2,066.99% -1,383.65% -1,709.62% -785.58%
EPS 2 -158.0 -137.2 -44.25 -7.200 -7.052 -3.483
Free Cash Flow 1 -1.994 2.127 -6.219 -9.002 -7.028 -8.529
FCF margin -141.22% 150.66% -496.62% -633.66% -466.82% -479.13%
FCF Conversion (EBITDA) - - - - - -
FCF Conversion (Net income) - - - - - -
Dividend per Share - - - - - -
Announcement Date 4/1/19 4/1/20 3/15/21 3/31/22 3/21/23 3/28/24
1USD in Million2USD
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2021 Q3 2021 Q4 2022 Q1 2022 Q3
Net sales 0.3137 0.4765 0.3146 -
EBITDA - - - -
EBIT -2.68 -4.416 -3.414 -
Operating Margin -854.35% -926.76% -1,085.31% -
Earnings before Tax (EBT) -5.438 -8.418 -3.371 -
Net income 1 -5.438 -7.757 -3.371 -4.059
Net margin -1,733.73% -1,627.84% -1,071.53% -
EPS 2 -1.600 -2.600 -1.000 -1.000
Dividend per Share - - - -
Announcement Date 11/10/21 3/31/22 5/12/22 11/10/22
1USD in Million2USD
Estimates

Balance Sheet Analysis

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Net Debt 1 1.47 5.37 5.2 - - -
Net Cash position 1 - - - 27.3 21.9 5.87
Leverage (Debt/EBITDA) -0.1909 x -0.468 x -0.4535 x - - -
Free Cash Flow 1 -1.99 2.13 -6.22 -9 -7.03 -8.53
ROE (net income / shareholders' equity) -735% -344% -373% -91.6% -83% -93.1%
ROA (Net income/ Total Assets) -134% -57.9% -44% -29.6% -27.5% -43.3%
Assets 1 7.527 33.5 58.78 66.34 93.74 32.27
Book Value Per Share 2 0.7500 55.20 2.670 12.30 5.530 2.040
Cash Flow per Share 2 2.300 0.7400 0.6900 8.600 5.600 2.150
Capex 1 0.18 0.01 0.3 0.91 0.42 0.28
Capex / Sales 12.59% 0.42% 23.83% 64.08% 27.89% 15.52%
Announcement Date 4/1/19 4/1/20 3/15/21 3/31/22 3/21/23 3/28/24
1USD in Million2USD
Estimates
  1. Stock Market
  2. Equities
  3. POAI Stock
  4. Financials Predictive Oncology Inc.